CD137 Antibody (G-1): sc-365371
- CD137 Antibody (G-1) is a mouse monoclonal IgM κ, cited in 1 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 33-61 near the N-terminus of CD137 of human origin
- recommended for detection of CD137 of human origin by WB, IP, IF and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD137 Antibody (G-1). This work is in progress.
QUICK LINKS
CD137 Antibody (G-1) is a mouse monoclonal IgM antibody that detects CD137 in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). CD137, also known as ILA or 4-1BB in mice, is a member of the tumor necrosis factor receptor family and plays a crucial role in the immune response by delivering costimulatory signals to T lymphocytes. CD137 is primarily expressed on activated T cells and interacts with its inducible ligand found on B cells, macrophages, and dendritic cells, which is essential for effective antigen presentation and the generation of cytotoxic T cells. CD137′s ability to regulate peripheral monocyte survival through the induction of a specific cytokine release profile highlights CD137′s importance in maintaining immune homeostasis. The interaction between CD137 and its ligand not only promotes T cell activation but also influences the apoptosis of resting lymphocytes, showcasing CD137′s dual role in immune regulation. Soluble forms of CD137 have been detected in the sera of patients with rheumatoid arthritis, suggesting a potential negative feedback mechanism in immune responses, which underscores CD137′s significance in both health and disease. Anti-CD137 antibody (G-1) is an invaluable tool for researchers aiming to explore the complexities of immune signaling and the therapeutic potential of targeting this pathway.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD137 Antibody (G-1) References:
- Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy. | Sanchez-Paulete, AR., et al. 2016. Eur J Immunol. 46: 513-22. PMID: 26773716
- CD137 and CD137L signals are main drivers of type 1, cell-mediated immune responses. | Dharmadhikari, B., et al. 2016. Oncoimmunology. 5: e1113367. PMID: 27141396
- The Roles of CD137 Signaling in Atherosclerosis. | Jung, IH. and Oh, GT. 2016. Korean Circ J. 46: 753-761. PMID: 27826331
- The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention. | Luu, K., et al. 2020. J Leukoc Biol. 107: 731-738. PMID: 32052477
- CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. | Hashimoto, K. 2021. Cancers (Basel). 13: PMID: 34064598
- Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. | Glez-Vaz, J., et al. 2022. J Immunother Cancer. 10: PMID: 35236742
- CD137 Signal Mediates Cardiac Ischemia-Reperfusion Injury by Regulating the Necrosis of Cardiomyocytes. | Xu, Y., et al. 2022. J Cardiovasc Transl Res. 15: 1163-1175. PMID: 35419772
- Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy. | Zhang, H., et al. 2024. Cancer Treat Res Commun. 39: 100805. PMID: 38492435
- CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line. | Gelibter, A., et al. 2024. J Transl Med. 22: 329. PMID: 38570798
- CD137-expressing regulatory T cells in cancer and autoimmune diseases. | Lee, KY., et al. 2025. Mol Ther. 33: 51-70. PMID: 39668561
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD137 Antibody (G-1) | sc-365371 | 200 µg/ml | $322.00 | |||
CD137 (G-1) Neutralizing Peptide | sc-365371 P | 100 µg/0.5 ml | $69.00 |